Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 10,173 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74. Following the completion of the transaction, the chief executive officer owned 392,483 shares in the company, valued at $2,504,041.54. This trade represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock traded up $0.02 during midday trading on Friday, hitting $6.29. The company’s stock had a trading volume of 659,585 shares, compared to its average volume of 1,093,850. The company has a market cap of $459.11 million, a price-to-earnings ratio of -2.33 and a beta of 1.78. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $10.99. The company has a 50-day moving average price of $8.37 and a two-hundred day moving average price of $7.62.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC acquired a new position in Lexeo Therapeutics in the 2nd quarter worth about $60,000. Savant Capital LLC bought a new stake in shares of Lexeo Therapeutics during the second quarter worth about $119,000. Ethic Inc. acquired a new position in shares of Lexeo Therapeutics in the second quarter valued at approximately $44,000. Affinity Asset Advisors LLC raised its holdings in Lexeo Therapeutics by 142.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company’s stock valued at $14,429,000 after buying an additional 2,108,474 shares during the last quarter. Finally, CWM LLC boosted its position in Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after buying an additional 6,216 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price target on shares of Lexeo Therapeutics in a research note on Wednesday, December 10th. Raymond James Financial started coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Cantor Fitzgerald began coverage on shares of Lexeo Therapeutics in a research report on Monday, December 1st. They set an “overweight” rating and a $19.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Lexeo Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.